Who can join
Studies for children and teens
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
468 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
Elpida Therapeutics SPC
- Location
- Dallas, TX
- Eligibility basics
- Ages 4 mo–10
- RecruitingPhase 1/Phase 2
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Solid Biosciences Inc.
- Location
- Little Rock, AR + 11 other US sites
- Eligibility basics
- Ages 0 mo–17 · Men only
- RecruitingPhase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 6 mo–11
- RecruitingPhase 2
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
Pfizer
- Location
- San Diego, CA + 2 other US sites
- Eligibility basics
- Ages 10 mo–17
- RecruitingPhase 2
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals, Inc.
- Location
- Atlanta, GA
- Eligibility basics
- Ages 12–17
- Recruiting
To Assess the Utility of the Point Mini in a Clinical Take-home Study
Point Designs
- Location
- Atlanta, GA
- Eligibility basics
- Ages 3–17
- Recruiting
Establishing the Preliminary Utility of a Novel Pediatric Manual Mobile Standing Wheelchair
Optimal Mobility, Inc
- Location
- Saint Paul, MN
- Eligibility basics
- Ages 8–17
- RecruitingPhase 2/Phase 3
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Urovant Sciences GmbH
- Location
- Little Rock, AR + 6 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
Vanda Pharmaceuticals
- Location
- Dothan, AL + 18 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 4
Two Dose Levels of Privigen in Pediatric CIDP
CSL Behring
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 2–17
- Recruiting
A Study to Evaluate a New Semi-rigid Brace, the RESILIENT Brace by Thinks Works, as a Way to Limit Curve Worsening in Kids With Idiopathic Scoliosis.
Thinks Works, PBC
- Location
- Wilmington, DE
- Eligibility basics
- Ages 9–16
- RecruitingPhase 3
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic…
Takeda
- Location
- Wilmington, DE + 7 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
BioMarin Pharmaceutical
- Location
- California City, CA + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- San Francisco, CA + 6 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Travere Therapeutics, Inc.
- Location
- Los Angeles, CA + 16 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Takeda
- Location
- Atlanta, GA + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Tetraphase Pharmaceuticals, Inc
- Location
- Los Angeles, CA + 4 other US sites
- Eligibility basics
- Ages 8–17
- RecruitingPhase 2
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
Gilead Sciences
- Location
- Atlanta, GA
- Eligibility basics
- Up to age 17
- RecruitingPhase 2/Phase 3
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
- Location
- New Haven, CT + 3 other US sites
- Eligibility basics
- Ages 0 mo–17
- RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC
- Location
- Los Angeles, CA + 8 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Elpida Therapeutics SPC
- Location
- Dallas, TX
- Eligibility basics
- Ages 4 mo–6
- RecruitingPhase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
AMAG Pharmaceuticals, Inc.
- Location
- Kansas City, MO + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
AMAG Pharmaceuticals, Inc.
- Location
- Miami, FL + 2 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1/Phase 2
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Aspa Therapeutics
- Location
- Oakland, CA + 2 other US sites
- Eligibility basics
- Up to age 2
Questions
If I fit this group, will I qualify?
Not necessarily. Age and sex limits are only the first filter. Each study has its own inclusion and exclusion criteria, and the research team decides at screening.
Where do these age and sex limits come from?
From the eligibility section of each study’s official ClinicalTrials.gov record. We don’t infer eligibility from anything else.